935106861
info@markelab.com
Precio
412.5€ (100 µg)
Gosuranemab is a monoclonal antibody biosimilar expressed in CHO cells, targeting MAPT, Gosuranemab (BIIB092) is a humanized IgG4 monoclonal anti-antibody targeting the N-terminal tau protein (eTau). The basic principle of this treatment method is based on the hypothesis that eTau is involved in the spread of pathological diseases.
Biosimilars
Human, Mouse
Monoclonal
Human
MAPT
Human, Mouse
IgG4 Kappa
Unconjugated
Liquid
ELISA, WB
100 µg
1 mg
Recombinant
> 95%
Purified from cell culture supernatants by Protein A/G chromatography.
0.01 M PBS. pH 7.4.
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
No
Shipped within 7-12 working days.
Biosimilars
CAS Number 1788032-39-2
Precio a consultar
Ver másPrecio a consultar
Ver másPrecio a consultar
Ver más